Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 6Lymphoma 6Lymphoma, Non-Hodgkin 4Melanoma 2Hodgkin Disease 2Wilms Tumor 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

Imatinib Mesylate 13bosutinib 3Vincristine 3Dexamethasone 3Dasatinib 3Cyclophosphamide 3nilotinib 2fludarabine phosphate 2fludarabine 2Methotrexate 2Daunorubicin 2Cytarabine 2Azacitidine 2Acetaminophen 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1peginterferon alfa-2a 1flumatinib 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Prednisone 1Prednisolone 1Mycophenolic Acid 1Mitoxantrone 1Mercaptopurine 1Melphalan 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Philadelphia Chromosome × Blood Component Removal × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡